Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biohaven Ltd. Common Shares
(NY:
BHVN
)
15.61
+0.93 (+6.34%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biohaven Ltd. Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Biohaven Stock Zoomed More Than 6% Higher Today
August 22, 2025
It's always encouraging to get what appears to be good news from the FDA.
Via
The Motley Fool
Topics
Regulatory Compliance
Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News?
August 22, 2025
Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug.
Via
Investor's Business Daily
Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting
August 22, 2025
Biohaven shares rise as FDA removes advisory committee meeting for troriluzole in spinocerebellar ataxia, with decision expected in late 2025.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
August 22, 2025
Via
Benzinga
Why Biohaven Stock Triumphed on Tuesday
February 11, 2025
Via
The Motley Fool
What's Going On With Merus Stock Monday?
January 13, 2025
Merus announced a research collaboration and license agreement with Biohaven.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 30, 2025
Via
Benzinga
Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday
July 30, 2025
Via
Benzinga
Traders are paying attention to the gapping stocks in Wednesday's session.
July 30, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
July 07, 2025
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Via
Stocktwits
Why Biohaven Stock Dove by Nearly 20% on Thursday
May 15, 2025
Via
The Motley Fool
Why Is Biohaven Stock Falling On Thursday?
May 15, 2025
Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.
Via
Benzinga
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug
May 15, 2025
The company hadn't expected an advisory committee meeting, nor a three-month pushback for its rare-disease drug review.
Via
Investor's Business Daily
Red Cat Holdings, Alibaba, DXC Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
May 15, 2025
Via
Benzinga
Why BioHaven Stock Is Soaring Today
April 28, 2025
Via
The Motley Fool
Topics
Stocks
Biohaven Rallies On Heels Of $600M Funding Agreement With Oberland
April 28, 2025
Biohaven Ltd. (BHVN) shares rise premarket as it secures up to $600 million investment from Oberland Capital. Cash reserves expected to reach $489 million.
Via
Benzinga
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
April 28, 2025
Via
Benzinga
Why Biohaven Stock Plummeted by More Than 15% Today
April 25, 2025
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 18, 2025
Via
Benzinga
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
April 03, 2025
Via
The Motley Fool
Topics
Bankruptcy
Economy
World Trade
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
March 04, 2025
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Via
Investor's Business Daily
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
March 03, 2025
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.
Via
Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
March 03, 2025
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...
Via
Benzinga
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
February 11, 2025
The company could soon add a new, high-value treatment to its portfolio.
Via
Investor's Business Daily
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
January 26, 2025
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory...
Via
Benzinga
Topics
Regulatory Compliance
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
December 17, 2024
Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.
Via
Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.
Via
Benzinga
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
November 25, 2024
Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.
Via
Benzinga
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.